Johanna Mercier - Gilead Sciences Chief Commercial Officer

All Insiders . Mexico . 
Stock . Gilead Sciences . Stakeholders . Insider . Johanna Mercier
GILD Stock  MXN 1,892  79.51  4.39%   

Executive

Ms. Johanna Mercier is Chief Commercial Officer of the Company since 2019.
Age 53
Tenure 5 years
Professional MarksMBA
Phone650 574 3000
Webhttps://www.gilead.com
Mercier is a proven leader who brings to Gilead deep experience in worldwide and senior operational roles in geographies around the globe. She has held leadership positions in therapeutic areas including oncology, inflammation and neuroscience. She joins Gilead from BristolMyers Squibb, where she most recently served as President and Head of the company Large Markets division, which includes the United States, France, Germany and Japan. Over the course of her career, she has helped drive growth across key markets, pioneered innovative access strategies in the United States and Europe and helped establish new standards of care for people with cancer. In addition to her executive position at BristolMyers, Ms. Mercier is a director on the Robert Wood Johnson University Hospital Board. She holds a MBA from Concordia University and a BSs in Biology from the University of Montreal.

Johanna Mercier Latest Insider Activity

Tracking and analyzing the buying and selling activities of Johanna Mercier against Gilead Sciences stock is an integral part of due diligence when investing in Gilead Sciences. Johanna Mercier insider activity provides valuable insight into whether Gilead Sciences is net buyers or sellers over its current business cycle. Note, Gilead Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Gilead Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
 
Johanna Mercier over six months ago
Acquisition by Johanna Mercier of 20086 shares of Gilead Sciences subject to Rule 16b-3

Gilead Sciences Management Efficiency

The company has return on total asset (ROA) of 0.1045 % which means that it generated a profit of $0.1045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.216 %, meaning that it generated $0.216 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities.
Gilead Sciences has accumulated 25.18 B in total debt with debt to equity ratio (D/E) of 122.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences has a current ratio of 3.55, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Gilead Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Gilead Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Gilead Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Gilead to invest in growth at high rates of return. When we think about Gilead Sciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records

EXECUTIVE Age

Heather MellohAmeriprise Financial
N/A
John HuttAmeriprise Financial
48
Joseph SweeneyAmeriprise Financial
62
Enrique GuerreroGrupo Hotelero Santa
54
Jake LawrenceThe Bank of
N/A
Gabriela PalaciosGrupo Hotelero Santa
52
William DaviesAmeriprise Financial
59
Ignacio DeschampsThe Bank of
N/A
Dawn BrockmanAmeriprise Financial
N/A
Gerard SmythAmeriprise Financial
61
Francisco ElizaldeGrupo Hotelero Santa
62
William TruscottAmeriprise Financial
63
James NeateThe Bank of
N/A
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD SCIENCES operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 11000 people. Gilead Sciences (GILD) is traded on Mexican Exchange in Mexico and employs 38 people.

Management Performance

Return On Equity0.22
Return On Asset0.1

Gilead Sciences Leadership Team

Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Daniel ODay, Chairman of the Board, CEO
Johanna Mercier, Chief Commercial Officer
Deborah Telman, Gen Affairs
Jyoti Mehra, Ex HR
Jacquie CFA, VP Relations
Diane Wilfong, Corp VP
Andrew Dickinson, Executive Vice President - Corporate Development and Strategy
Michael Quigley, VP Biology
Linda Higgins, VP Innovation

Gilead Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.22
Return On Asset0.1
Profit Margin0.17 %
Operating Margin0.40 %
Current Valuation2.55 T
Shares Outstanding1.25 B
Shares Owned By Institutions84.16 %
Price To Earning282.94 X
Price To Book5.19 X
Price To Sales79.06 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
TITANTitan Company Limited
UUnity Software
PAYCPaycom Soft

Additional Tools for Gilead Stock Analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY